Esperion Therapeutics Stock Performance
| ESPR Stock | USD 2.75 0.10 3.77% |
Esperion Therapeutics holds a performance score of 21 on a scale of zero to a hundred. The firm shows a Beta (market volatility) of 0.46, which means possible diversification benefits within a given portfolio. As returns on the market increase, Esperion Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Esperion Therapeutics is expected to be smaller as well. Use Esperion Therapeutics value at risk, as well as the relationship between the kurtosis and market facilitation index , to analyze future returns on Esperion Therapeutics.
Risk-Adjusted Performance
Solid
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Esperion Therapeutics are ranked lower than 21 (%) of all global equities and portfolios over the last 90 days. Even with relatively weak basic indicators, Esperion Therapeutics reported solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 82.2 M | |
| Total Cashflows From Investing Activities | -317 K |
Esperion Therapeutics Relative Risk vs. Return Landscape
If you would invest 115.00 in Esperion Therapeutics on July 20, 2025 and sell it today you would earn a total of 160.00 from holding Esperion Therapeutics or generate 139.13% return on investment over 90 days. Esperion Therapeutics is currently generating 1.4989% in daily expected returns and assumes 5.5248% risk (volatility on return distribution) over the 90 days horizon. In different words, 49% of stocks are less volatile than Esperion, and 70% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Esperion Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Esperion Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Esperion Therapeutics, and traders can use it to determine the average amount a Esperion Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.2713
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ESPR | |||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 5.52 actual daily | 49 51% of assets are more volatile |
Expected Return
| 1.5 actual daily | 30 70% of assets have higher returns |
Risk-Adjusted Return
| 0.27 actual daily | 21 79% of assets perform better |
Based on monthly moving average Esperion Therapeutics is performing at about 21% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Esperion Therapeutics by adding it to a well-diversified portfolio.
Esperion Therapeutics Fundamentals Growth
Esperion Stock prices reflect investors' perceptions of the future prospects and financial health of Esperion Therapeutics, and Esperion Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Esperion Stock performance.
| Return On Equity | -2.61 | |||
| Return On Asset | -0.0634 | |||
| Profit Margin | (0.39) % | |||
| Operating Margin | 0.09 % | |||
| Current Valuation | 800.91 M | |||
| Shares Outstanding | 231.62 M | |||
| Price To Earning | (8.19) X | |||
| Price To Book | 98.42 X | |||
| Price To Sales | 2.38 X | |||
| Revenue | 332.31 M | |||
| EBITDA | 7.57 M | |||
| Cash And Equivalents | 185.84 M | |||
| Cash Per Share | 2.79 X | |||
| Total Debt | 591.21 M | |||
| Book Value Per Share | (2.17) X | |||
| Cash Flow From Operations | (23.65 M) | |||
| Earnings Per Share | (0.54) X | |||
| Total Asset | 343.82 M | |||
| Retained Earnings | (1.6 B) | |||
| Current Asset | 214.39 M | |||
| Current Liabilities | 5.62 M | |||
About Esperion Therapeutics Performance
Assessing Esperion Therapeutics' fundamental ratios provides investors with valuable insights into Esperion Therapeutics' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Esperion Therapeutics is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan. Esperion Theraptc operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 218 people.Things to note about Esperion Therapeutics performance evaluation
Checking the ongoing alerts about Esperion Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Esperion Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Esperion Therapeutics is way too risky over 90 days horizon | |
| Esperion Therapeutics appears to be risky and price may revert if volatility continues | |
| Esperion Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 332.31 M. Net Loss for the year was (51.74 M) with profit before overhead, payroll, taxes, and interest of 123.96 M. | |
| Esperion Therapeutics currently holds about 185.84 M in cash with (23.65 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.79, which can makes it an attractive takeover target, given it will continue generating positive cash flow. |
- Analyzing Esperion Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Esperion Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Esperion Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Esperion Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Esperion Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Esperion Therapeutics' stock. These opinions can provide insight into Esperion Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Esperion Stock Analysis
When running Esperion Therapeutics' price analysis, check to measure Esperion Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Esperion Therapeutics is operating at the current time. Most of Esperion Therapeutics' value examination focuses on studying past and present price action to predict the probability of Esperion Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Esperion Therapeutics' price. Additionally, you may evaluate how the addition of Esperion Therapeutics to your portfolios can decrease your overall portfolio volatility.